ArticleScientific reports2017
A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Network controllability analysis reveals the antiviral potential of Etravirine against hepatitis E virus infection.mSystems · 2025Article
- Article
- Hepatitis E Virus Protease Inhibits the Activity of Eukaryotic Initiation Factor 2-Alpha Kinase 4 and Promotes Virus Survival.Journal of virology · 2023Article
- Engineering highly thermostable Cas12b via de novo structural analyses for one-pot detection of nucleic acids.Cell reports. Medicine · 2023Article
- Antiviral Activity of Zinc Oxide Nanoparticles and Tetrapods Against the Hepatitis E and Hepatitis C Viruses.Frontiers in microbiology · 2022Article
- Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health.Pathogens (Basel, Switzerland) · 2020Review
- Hepatitis E Virus ORF2 Inhibits RIG-I Mediated Interferon Response.Frontiers in microbiology · 2020Article
- Hepatitis E Virus Drug Development.Viruses · 2019Review
- Development of a fluorescence-based method for the rapid determination of Zika virus polymerase activity and the screening of antiviral drugs.Scientific reports · 2019Article
- Recent Advances Towards the Development of a Potent Antiviral Against the Hepatitis E Virus.Journal of clinical and translational hepatology · 2018Review
- In vitro methods for testing antiviral drugs.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) is a global pathogen and infects more than 185 million individuals worldwide. Although recent development of direct acting antivirals (DAA) has shown promise in HCV therapy, there is an urgent need for the development of more affordable treatment options. We initiated this study to identify novel inhibitors of HCV through screening of compounds from the National Cancer Institute (NCI) diversity dataset. Using cell-based assays, we identified NSC-320218 as a potent inhibitor against HCV with an EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.